The objectives of this study were to evaluate the outcome after polychemotherapy for patients with primary cutaneous largecell lymphomas (PCLL) and to validate the recently proposed immunohistologic classification of cutaneous lymphomas. Among 140 patients with positive skin biopsies included in the LNH87 protocol (for treatment of aggressive lymphomas), 49 patients met the criteria of PCLL. Characteristics were: sex ratio M/F, 2.3; age 18 to 83 years (median, 52), peripheral lymph nodes, n = 22; diffuse disease, n = 12; median tumor size, 4.5 cm; elevated lactate dehydrogenase, n = 9; ECOG: 0/1, n = 49. Histology was: follicular center B cell, n = 23; B-lymphoblastic, n = 1; anaplastic large-cell lymphoma, n = 14 (T cell phenotype n = 8); CD30 ؊ T cell lymphoma, n = 11. All patients received polychemotherapy: under 70 years, ACVBP (three to four cycles and consolidation for 6 months) n = 25; mBACOD (eight cycles) n = 16; over 70 years, C(T)VP (six cycles) n = 8. Radiation therapy was not included in the protocol. With a median follow-up of 5 years, 24/49 patients had relapsed, with 20 skin relapses. Event-free (EFS) and overall survival (OS) at 5 years were, respectively, 50 and 77%. Significant adverse prognostic factors were: histology (CD30 ؊ T cell lymphoma) and diffuse cutaneous disease (Ͼ Ͼ Ͼ10% of skin). The presence of nodal involvement was only significant for EFS. When compared to 140 non-cutaneous lymphoma patients included in the same trial and fully matched for the main clinical characteristics, OS was similar. In conclusion, PCLL behaves like other localized B or T cell extranodal lymphomas with the same prognostic factors (LDH, ECOG, age) except for CD30
Introduction
Cutaneous lymphomas can be defined as a heterogeneous group of extranodal lymphomas that clinically originate in the skin. 1 For many decades, mycosis fungoides and Sézary syndrome have been the only well-defined clinicopathologic entities within this group of diseases. The advent of immunohistochemical studies using monoclonal antibodies that can specifically identify B and T lymphocytes had a major impact on the diagnosis and classification of cutaneous lymphomas. 2 Primary cutaneous large-cell lymphomas (PCLL) were initially thought to be a manifestation of systemic lymphoma. Later, based on detailed clinicopathologic studies of well-defined groups of cutaneous lymphomas, it became clear that some types of malignant lymphomas can arise exclusively in the skin without concurrent extracutaneous disease. 1 Recent studies on PCLL, have been able to define distinct clinicopathologic entities. B-large cell lymphomas are mostly of follicle center cell origin and T-large cell lymphomas are classified according to the CD30 antigen expression which identify anaplastic large-cell lymphomas having a good prognosis. [3] [4] [5] Correspondence: P Brice, Hô pital Saint-Louis, 1, avenue ClaudeVellefaux, 75475 Paris Cedex 10, France; Fax: 33 1 42 49 92 92 Received 9 July 1997; accepted 21 October 1997 Furthermore, these PCLL may have clinical behaviors and prognoses different from those of primary node-based malignant lymphomas of the same histologic subtype. 3, 6 Treatment has not yet been well-defined, comprising radiotherapy, polychemotherapy or both, 7, 8 and no prospective studies have been performed in this rare and heterogeneous group of patients. After treatment, survival rates ranged from 30 to 80% and the worst prognosis is observed in CD30
− Tlarge cell lymphomas. 5, 7 For these reasons, PCLL patients included in the multicentric prospective trial of polychemotherapy (LNH87) for the treatment of aggressive lymphomas were selected and their therapeutic results, histologic features and prognostic factors for survival were analyzed. These patients were then compared to those presenting with noncutaneous lymphomas included in the same protocol and fully matched for the main clinical characteristics (age, LDH level, ECOG scale, non cutaneous extranodal site). 
Patients and methods

Eligibility criteria
In October 1987, the Groupe d'Etudes des Lymphomes de L'Adulte undertook a multicentric prospective trial with over 50 participating centers in France and Belgium. Study eligibility requirements were: newly diagnosed patients over 15 years old with intermediate/high-grade non-Hodgkin's lymphomas according to the Working Formulation. 9 Patients were then stratified according to their age and known prognostic factors: ECOG performance status Ͼ1, bone marrow involvement, tumor burden у10 cm, central nervous system involvement, у2 extranodal sites. Patients were excluded if they were human immunodeficiency virus-positive, had a concomitant or previous cancer, congestive heart failure recent myocardial infarction, liver or kidney failure. This study was approved by the institutional Ethics Committee and patients gave their informed consent.
Diagnosis of PCLL
Cutaneous lymphoma was diagnosed based on skin biopsy and was defined as primary when the skin was the first manifestation of the disease and after normal bone marrow biopsy and thoracoabdominal computed tomography scan. Among 140 patients with histologic skin involvement included in the LNH87 protocol, 55 patients met the previously defined criteria of PCLL.
1 Six patients were subsequently excluded for various reasons: wrong history (n = 3; two myeloid leukemia, one benign lymphoid hyperplasia), lost to follow-up (n = 1), insufficient clinical data (n = 2). No patient was excluded after histological review and modification of the lymphoma classification. Clinical presentation was as nodule(s) or tumor(s), the localization of the skin lesions was reported and the presence or not of peripheral nodal involvement. The diameter of the largest skin tumor was also determined. Previous cutaneous history was assessed when possible.
Staging procedure
Performance status was based on the ECOG scale (0 to 4). Serum LDH was expressed as a percentage of the maximal normal value. The Ann Arbor classification was not useful in these patients because cutaneous involvement is considered a single extranodal site. All clinical data on the 49 PCLL patients were reviewed and patients were classified according to the extent of cutaneous disease. Patients with Ͻ10% of their skin surface involved with lymphoma were considered to have localized disease, the others were classified as having diffuse cutaneous disease. When applicable, the localization and histology of the relapse was noted.
Histologic and immunophenotypic analyses
Three independent hematopathologists, members of the Groupe d'Etudes des Lymphomes de l'Adulte, performed the histologic examinations and their observations were used for the analysis of patients. The Ki1 anaplastic large-cell subtype was added to the updated Kiel classification. 10, 11 For the present study, cutaneous sections were available for 94% of patients and reviewed together by a hematopathologist and a dermapathologist (DC, OV) and classified according to the EORTC recent classification of primary cutaneous lymphoma, with corresponding lymphoma types in Kiel and REAL classifications. 12 Immunophenotypic studies were performed on deparaffinized tissue sections as previously described, 13 using a panel of antibodies directed against B (CD20) and T (CD3, CD7) cell-associated antigens. For T cell and anaplastic lymphomas the expression of CD30 antigen was evaluated.
Treatment
Forty-nine patients were enrolled in the LNH87 protocol, whose goals were briefly to compare the LNH84 protocol 14 with another chemotherapeutic regimen in patients under 70 years of age and stratified in prognostic subgroups according to factors previously described, and to assess the impact of anthracycline on survival in patients over 69 years old.
More precisely, 25 patients received the LNH84 intensive regimen: ACVBP (adriamycin 75 mg/m 2 and cyclophosphamide 1200 mg/m 2 on day 1, vindesine 2 mg/m 2 and bleomycin 10 mg on days 1 and 5, and prednisone 60 mg/m 2 on days 1 to 5) three or four cycles every 2-3 weeks, then consolidation (n = 24) consisting of sequential cycles with methotrexate, ifosfamide, etoposide, l-asparaginase and cytarabine for 4 months. One patient recieved late intensification with highdose therapy (CBV) and autologous bone marrow transplantation. 15 9 /l and platelet count above 100 000 × 10 9 /l. No radiation therapy was recommended in the protocol, but 2/49 patients received radiotherapy to localized cutaneous lesions.
Assessment of response
Response to treatment was evaluated at the end of therapy. Tumor response was considered as complete (CR) or partial (PR) in accordance with standard guidelines. 14 
Statistical methods
Analysis of data from PCLL patients:
The stopping date for the present analysis was set at 1 September 1995. The study endpoints were the response rate, event-free (EFS) and overall survival (OS). EFS was calculated from the time of randomization to the date of progression, relapse or death. OS rates were measured from the date of randomization to the date of death (regardless of the cause) or the stopping date. All analyses were performed on an intention-to-treat basis. Survival rates were estimated using the Kaplan and Meier method and were compared using the log-rank test. 16 Variables analyzed as prognostic indicators included the following: age (р or Ͼ60 years); localized or diffuse cutaneous disease (р or Ͼ10%); LDH Ͼ100% above the normal range at diagnosis, nodal involvement, localization of the disease including or not the inferior limb, time between the first cutaneous manifestation and the start of treatment, maximal tumor size, histologic type. Test statistics for comparison of major endpoints were regarded as significant when the two-sided P value was р0.05. Statistical analyses were conducted with SAS version 6 (Cary, NC, USA).
Case-controlled studies:
We performed a case-controlled study by matching the PCLL patients with non-Hodgkin's lymphoma patients also included in the prospective protocol LNH87 but without cutaneous involvement. The International Prognosis Index 9 was not used for matching, because the Ann Arbor staging is not relevant in PCLL. The 49 patients with PCLL were fully matched to 150 patients (ratio: 1/3) having extranodal lymphoma (stage IE, IIE) for each of the following clinical characteristics: age, ECOG, LDH level. Because immunohistology is the main prognostic factor in PCLL, a second matching was performed for only B cell lymphomas. This approach could not be applied to T cell lymphomas because of the too few localized extranodal lymphomas in this group of patients.
Results
Patient outcome
The main characteristics of the 49 patients with PCLL are given (Table 1) according to immunohistologic subtype: Blarge cell lymphoma (n = 24), CD30
+ anaplastic-cell lymphoma (n = 14), and CD30
− T cell lymphoma (n = 11). Age ranged from 18 to 83 years (median, 52 years). There was a male predominance with an M/F ratio of 2.3. Six patients had previous skin diseases, erythrodermia, parapsoriasis or lymphoid papulosis (n = 4) (T cell lymphomas), surgical excision of a cutaneous nodule diagnosed as 'pseudolymphoma' (n = 2) (B cell lymphomas). Two patients had previous autoimmune disease Behçet's disease (n = 1) and primary biliary cirrhosis (n = 1). Twelve patients had diffuse cutaneous disease and 37 patients had localized cutaneous disease (Ͻ10% of the skin) in one or more sites: the median maximal tumor size was 4.5 cm. Twenty-two patients had peripheral lymph node involvement contiguous to cutaneous lesions. Nine patients had LDH levels above the normal value and all had ECOG score of 0-1. At the end of treatment, 39 patients (80%) had achieved a CR. No patient died from toxicity of chemotherapy.
Histology
Three cases were not classified because histological tissue was insufficient for analysis (n = 1), or for a complete immunohistochemistry (n = 2). Histological classification of the remaining 46 cases was made according to the updated Kiel classification, 10 REAL classification 11 and EORTC classification. 12 A summary is given in Table 2 . Among primary cutaneous B cell lymphomas (n = 24), we observed two subtypes of lymphoproliferation. The great majority of cases presented with large diffuse tumoral lesion with monomorphous histological pattern, made of centroblasts admixed with some immunoblasts. The infiltrate was dense and covered the dermis and hypodermis as large bands, without epidermotropism. Reactive follicles were never seen. Admixed reactive small T cells were generally rare and eosinophils or neutrophils absent. Only one case showed a nodular architecture. On the other hand, in three cases we observed a more heterogeneous infiltrate adopting a perivascular or periadnexal distribution and made of smallto-medium size lymphocytes, plasma cells, centrocyte-like cells or monocytoid cells and scattered blasts cells (centroblasts). Two of them had numerous centroblasts and were classified as centroblastic lymphoma. The last one had a typical MALT-type lymphoma pattern (classified immunocytoma in the EORTC or Kiel classification) and corresponding to a marginal zone B cell lymphoma in REAL classification. One case (patient 24) had a lymphoblastic lymphoma. Pri- (14) Centroblastic/centrocytic (1) Follicle center (1) Immunocytoma (1) Immunocytoma (1) Extranodal marginal zone B cell (1) Other (1) Lymphoblastic (1) Lymphoblastic (1) Undetermined (1) Undetermined (1) Undetermined (1) CD30 + LTCL (14) CD30 + large T cell anaplastic (12) Large cell anaplastic (12) Anaplastic large cell (12) CD30 + large T Pleomorphic, medium/large cell (1) Peripheral T cell Pleiomorphic (1) Undetermined (1) Unspecified (1) Undetermined (1) Undetermined (1) CD30 − LTCL (11) CD30 large T cell pleomorphic (7) Pleomorphic medium/large cell (7) Peripheral T cell unspecified (7) Other (3) Angio-immunoblastic (3) Angio-immunoblastic (3) Undetermined (1) Undetermined (1) Undetermined (1) LBCL, large B cell lymphoma; LCL, large cell lymphoma; LTCL, large T cell lymphoma. + large cell lymphoma was classified as pleomorphic large cell lymphoma with a predominance of CD30 + tumoral cells. Eleven primary cutaneous T cell lymphomas did not express CD30: a large majority of them had the morphology of medium and large pleomorphic CD3
+ cells (seven cases). Three cases corresponded to angioimmunoblastic lymphomas, two of them diagnosed on regional lymph node biopsy specimens. The inclusion of these three cases as primary cutaneous lymphoma could be criticized (all of them had lymph node involvement at presentation), but clinical staging, and follow-up did not support evidence of secondary cutaneous lymphoma.
Failures
Nine patients progressed before the end of therapy and 15 (37%) patients relapsed (median time to relapse: 8 months). Relapses occurred in all histologic subtypes: 10/11 relapses in CD30
− T large-cell lymphomas, 8/24 in B large-cell lymphomas, 5/14 in CD30 + anaplastic-cell lymphomas. Sites of relapse were cutaneous in 20/24 patients (skin alone, n = 17), nodal in eight cases, one spleen localization and there were only three extranodal relapses (bone marrow, thyroid and central nervous system). Of 24 patients in relapse, 16 had a second cutaneous biopsy; immunohistology was the same as that found initially for 12 of them and of a lower grade in the others. Two patients initially diagnosed as having CD30 + anaplastic-cell lymphoma had lymphoid papulomatosis at relapse and two patients with CD30
− T large-cell lymphoma were considered to have epidermotropic small T cell lymphoma (mycosis fungoides) at relapse. The documented treatments prescribed for the relapse of 22 patients were: chemotherapy, n = 11; radiotherapy, n = 6; both, n = 1; high-dose therapy, n = 4. A second skin relapse was observed in six patients. At present, 12 patients have died; they had all experienced disease progression, but two of them died from intercurrent disease after progression (metastatic adenocarcinoma and cerebral ischemia).
Figure 1
Overall survival of PCLL patients according to histologic subtype: T anaplastic (n = 14) (%), B large-cell (n = 23) ( ), CD30 − T large-cell lymphoma (n = 13) (-) (P Ͻ 0.01).
Survival and prognostic factors
With a median follow-up of 60 months, EFS and OS were respectively, 50 and 77% at 5 years. Among all prognostic factors studied, dissemination of the cutaneous disease and histology (Figures 1 and 2 ) were found to be significant for EFS and OS. Patients with CD30
− T large-cell lymphoma had the worst prognosis; cutaneous disease affected Ͼ10% of the skin in 50% of them. For the other histologic groups, disease dissemination strongly influenced the EFS but not the OS, because of the fewer recorded deaths. Anaplastic PCLL had a
Figure 2
Overall survival of PCLL patients according to the dissemination of their cutaneous disease: diffuse disease Ͼ10% of the skin (n = 11) (-) and localized (n = 38) ( ), (P Ͻ 0.001).
very good prognosis and no patient died from lymphoma despite some relapses. The presence of peripheral lymph node involvement was only signficant for EFS (P Ͻ 0.05).
Case controlled studies
Our 49 PCLL patients could be matched with 150 patients included in the same prospective polychemotherapy trial. In this study matching was based on the main clinical characteristics. The control patients had localized extranodal lym-phoma but no cutaneous involvement. OS was similar in the two populations studied but, EFS was lower in PCLL patients (Table 3) .
Twenty-three patients with B cell PCLL could be further matched with 70 B-large cell lymphoma patients included in the prospective LNH87 trial. No differences between OS and EFS were noted in these patients subgroups.
Discussion
PCLL represents a heterogeneous group of malignant lymphomas for which the optimal treatment has not been found. Patients have been given various regimens from monochemotherapy to polychemotherapy or radiation therapy alone or associated with chemotherapy and experienced high relapse rates. [6] [7] [8] However, recent results have suggested that PCLL of the B cell type should not be treated with radiation therapy alone. 8 The use of polychemotherapy in this setting and results observed in nodal large-cell non-Hodgkin's lymphomas 8, 14 led us to include PCLL patients in a protocol of polychemotherapy for high-grade lymphomas (LNH87). This protocol has enrolled 3161 patients with high/intermediate-grade nonHodgkin's lymphoma. We analyzed the therapeutic results obtained in 49 patients presenting with PCLL and having prospectively been given polychemotherapy. From this study, we can confirm the heterogeneity of these patients, according to the immunophenotype and the three subgroups (B cell, CD30 + and CD30 − T cell lymphomas) which have very different prognoses in terms of EFS and OS. At 5 years, OS was respectively, 80, 100 and 35%. The International Prognostic Index could not be applied in this study to compare the patients because the Ann Arbor staging is not relevant for cutaneous lesions and, for other factors, the majority of the patients were in the low-intermediate group. On the other hand, we were able to confirm the significance of the extent of the disease, by defining patients with diffuse disease as those whose cutaneous lymphoma involved Ͼ10% of the skin. Patients with diffuse disease had significantly poorer prognoses in terms of EFS and OS even and most of them had CD30
− T large-cell lymphoma. EFS at 5 years was at 60% for patients with localized disease vs 20% for those with diffuse disease (P Ͻ 0.01). In contrast to a previous report, 8 the prognosis for patients with PCLL of the B cell type localized on the leg was not poor in our series; however, this discrepancy may be explained by the fact that all our patients received chemotherapy and the patient population was small. Under polychemotherapy, these patients had a relapse rate of 50%, which is lower than the relapse rate observed after radiation therapy alone or monochemotherapy. 7 We decided to compare the PCLL (n = 49) to other extranodal lymphoma (n = 150) matched according to the main clinical characteristics and treated with the same prospective protocol. EFS was significantly lower in patients with PCLL (65 vs 50%) but OS was similar, relapsed patients responded to salvage therapy including various treatments with radiation therapy in seven cases.
Anaplastic CD30 + large-cell lymphoma of the skin has been well recognized as having a very good prognosis and in our series no patients died of lymphoma. These patients should be treated with radiation therapy alone when the disease is localized without nodal involvement. 4 For the rare remaining patients, due to the high relapse rate, we think that chemotherapy is advisable, however, the optimal regimen is not yet known 17 but it must be chosen based on its low early and long-term toxicity in light of the long survival of these patients. For cutaneous B cell lymphoma, radiation therapy alone can only be recommended to patients whose disease is not localized to the leg and has no nodal involvement, nor elevated LDH and a good performance status. CD30
− T-large cell lymphoma of the skin has a very poor prognosis despite polychemotherapy. For these patients, more intensive regimens should be tested 18 or high-dose therapy with autologous stemcell transplantation. 15, 19 In conclusions, PCLL behave like other localized B or T large-cell extranodal lymphomas with the same prognostic factors (LDH level, ECOG score, age), except for CD30 + PCLL which have a better prognosis than nodal CD30 + malignant lymphomas. 20 Treatment should be tailored according to immunohistology and extent of the cutaneous disease.
